Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BINEX Co., Ltd. (053030.KQ)
KRW6,890.00
+190.00 (+2.84%)
KR KOE Healthcare Biotechnology
Address
7-48 SongDo-Dong 406-840
Incheon, KR
Incheon, KR
CEO
Won-Seok Kim
Website
bi-nex.co.kr
IPO
2001-08-07
ISIN KR7053030003
Description
BINEX Co., Ltd. operates as a pharmaceutical enterprise based in South Korea. The company provides an extensive array of medicinal products, encompassing bisroot items, gastrointestinal treatments (including antispasmodics and antiulcerants), NSAIDs, cardiovascular and urology medications, hepatic protective agents, topical ointments and creams, ophthalmic solutions, CNS agents, digestive aids, remedies for constipation and circulation, antibiotics and antifungals, cough and cold preparations, vitamins and nutritional supplements, antihistamines, antivertigo agents, and over-the-counter (OTC) drugs. Additionally, BINEX Co., Ltd. maintains a co-development alliance with Genexine, Inc. focused on the creation of a COVID-19 vaccine. Founded in 1957, its headquarters are situated in Incheon, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW6,890.00
+190.00 (+2.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
203.1K
Beta
0.28
Float Shares
27.57M
Free Float %
86.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37% | -8.84% | -23.76% | -40.34% | -34.30% | -41.42% | -44.09% | -19.50% | -60.69% | -50.65% | +377.89% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6,890.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.10
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+29.6% ★ Q1'26: -11.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+91.0% ★ Q1'26: -77,533.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-22.1% Q1'26: -24.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2.7% Q1'26: -25.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1.7% ★ Q1'26: -12.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×10.38× Q1'26: -4.82× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
71.14B
est: 71.25B (-0.2%)
|
80.92B
est: 83.30B (-2.9%)
|
78.03B
est: 114.30B (-31.7%)
|
104.04B
est: 155.00B (-32.9%)
|
125.26B
est: 160.20B (-21.8%)
|
132.98B
est: 133.00B (0.0%)
|
134.40B
est: 130.00B (+3.4%)
|
156.68B
est: 159.10B (-1.5%)
|
154.82B
est: 166.00B (-6.7%)
|
130.05B
est: 130.29B (-0.2%)
|
168.47B
est: 180.52B (-6.7%)
|
196.89B
196.89B – 196.89B
+9.1% YoY
|
227.50B
227.50B – 227.50B
+15.5% YoY
|
255.81B
255.81B – 255.81B
+12.4% YoY
|
| EBITDA |
5.17B
est: 5.91B (-12.6%)
|
6.22B
est: 6.91B (-10.0%)
|
-835.54M
est: 9.48B (-108.8%)
|
15.83B
est: 12.86B (+23.0%)
|
21.72B
est: 13.29B (+63.4%)
|
13.19B
est: 11.04B (+19.6%)
|
30.93B
est: 10.79B (+186.7%)
|
25.60B
est: 13.20B (+93.9%)
|
16.76B
est: 13.77B (+21.6%)
|
-24.20B
est: 9.67B (-350.2%)
|
9.36B
est: 13.40B (-30.2%)
|
14.62B
14.62B – 14.62B
+9.1% YoY
|
16.89B
16.89B – 16.89B
+15.5% YoY
|
18.99B
18.99B – 18.99B
+12.4% YoY
|
| EBIT |
-1.17B
est: 1.64B (-171.4%)
|
-1.86B
est: 1.92B (-197.3%)
|
-9.82B
est: 2.63B (-473.3%)
|
6.84B
est: 3.57B (+91.8%)
|
12.72B
est: 3.69B (+245.0%)
|
7.52B
est: 3.06B (+145.6%)
|
24.93B
est: 2.99B (+733.3%)
|
17.30B
est: 3.66B (+372.4%)
|
6.86B
est: 3.82B (+79.7%)
|
-36.63B
est: 823.65M (-4,547.4%)
|
-4.53B
est: 1.14B (-497.4%)
|
1.24B
1.24B – 1.24B
+9.1% YoY
|
1.44B
1.44B – 1.44B
+15.5% YoY
|
1.62B
1.62B – 1.62B
+12.4% YoY
|
| Net Income |
-6.81B
est: -700.52M (-872.5%)
|
-3.00B
est: 1.46B (-305.3%)
|
-11.29B
est: 8.87B (-227.3%)
|
6.34B
est: 16.41B (-61.4%)
|
8.50B
|
6.41B
est: 6.57B (-2.4%)
|
19.09B
est: 15.13B (+26.2%)
|
12.44B
est: 17.81B (-30.1%)
|
4.67B
est: 6.66B (-29.9%)
|
-35.07B
est: -24.93B (-40.7%)
|
-3.23B
est: 5.24B (-161.6%)
|
678.73M
678.73M – 678.73M
-87.0% YoY
|
9.74B
9.74B – 9.74B
+1,335.6% YoY
|
11.40B
11.40B – 11.40B
+17.0% YoY
|
| SGA |
24.43B
est: 23.19B (+5.3%)
|
29.20B
est: 27.12B (+7.7%)
|
34.54B
est: 37.21B (-7.2%)
|
39.44B
est: 50.46B (-21.8%)
|
43.25B
est: 52.15B (-17.1%)
|
44.49B
est: 43.30B (+2.8%)
|
45.92B
est: 42.32B (+8.5%)
|
50.87B
est: 51.79B (-1.8%)
|
53.86B
est: 54.04B (-0.3%)
|
36.28B
est: 39.10B (-7.2%)
|
34.97B
est: 54.18B (-35.5%)
|
59.09B
59.09B – 59.09B
+9.1% YoY
|
68.28B
68.28B – 68.28B
+15.5% YoY
|
76.78B
76.78B – 76.78B
+12.4% YoY
|
| EPS |
-231.64
est: -22.50 (-929.5%)
|
-97.69
est: 47.00 (-307.9%)
|
-367.27
est: 285.00 (-228.9%)
|
203.86
est: 527.00 (-61.3%)
|
272.69
|
205.58
est: 211.00 (-2.6%)
|
613.78
est: 486.00 (+26.3%)
|
402.42
est: 572.00 (-29.6%)
|
151.04
est: 214.00 (-29.4%)
|
-1,126.45
est: -780.38 (-44.3%)
|
-101.00
est: 163.94 (-161.6%)
|
21.25
21.25 – 21.25
-87.0% YoY
|
305.06
305.06 – 305.06
+1,335.6% YoY
|
356.97
356.97 – 356.97
+17.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-14.97B
OE per share TTM
-471.06
Owner's Yield
-5.05%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
81.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Biotech 244580.KS | 1.93% | 2.76M | 0.45% |
| 2 | Kodex Healthcare 266420.KS | 0.26% | 118.1K | 0.09% |
| 3 | Kodex KOSDAQ 150 229200.KS | 0.22% | 6.53M | 0.25% |
| 4 | SAMSUNG KODEX KOSDAQ150 LEVERAGE ETF 233740.KS | 0.07% | 1.51M | 0.64% |
| 5 | Samsung Kodex Fn Growth ETF 325010.KS | 0.03% | 26.3K | 0.30% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 172.0K | 0.06% |
| 7 | Vanguard FTSE Pacific ETF VPL | 0.00% | 160.0K | 0.07% |
| 8 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 2.7K | 0.22% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 82.0K | 0.39% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 58.5K | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-8.20M
Shares Outstanding
31.85M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Byung-In Lee | Head of Bus. Operation Division and Director | — | — |
| Doo-Hyun Kim | Vice President | — | — |
| Hyuk-Jong Lee | Managing Director | — | male |
| Jung-Jin Lee | Head of Bio-Tech Research Center and Director | — | — |
| Jung-Tak Moon | Chief Executive Officer | — | — |
| Jung-Won Seo | Head of Bio Processing Division and Director | — | — |
| Myung-Cheol Lee | Managing Director | — | — |
| Soo-Yong Jin | Managing Director | — | — |
| Won-Seok Kim | Head of Production Division and Director | — | — |
| Young-Cheol Son | Head of Management Support Division and Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 053030.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
